If you’re having hormone therapy for prostate cancer, you may notice changes in strength, balance or energy. Androgen deprivation therapy (ADT) can reduce muscle mass, increase fatigue and lower bone density. Weakness and tiredness may increase your risk of falling, while weaker bones can make fractures more likely.
Your risk may be higher if you’re older, have fallen before or struggle to walk. During long-term treatment, your doctor may assess bone health and fracture risk. Maintaining strength, balance and bone health can help you stay active and reduce falls and fractures.
Why Can Hormone Therapy Affect Your Risk of Falling?
If you’re taking hormone therapy, you may gradually lose some muscle strength as testosterone levels fall. You might also feel more tired, become less active or notice changes in your balance and physical performance, which can increase your risk of falling.
This doesn’t mean you’ll definitely become unsteady. Your age, fitness, other health conditions, medicines and how long you receive treatment all matter. Staying active and maintaining your strength can help you protect your mobility while you’re on hormone therapy.
Does ADT Weaken Your Muscles?
Yes. If you’re on ADT, lowering testosterone can gradually reduce muscle mass and strength. You may notice everyday tasks becoming harder, such as getting up from a chair, carrying shopping or climbing stairs. You may also find that you walk more slowly than before.
Resistance exercise can help you maintain the muscle strength needed for everyday activities and steady yourself if you stumble. Ask your doctor or physiotherapist which exercises are safe for you.
What Is Sarcopenia and Why Does It Matter?
If you’re having hormone therapy, you may develop muscle weakness and lose muscle mass over time. Sarcopenia is a muscle condition characterised by reduced muscle strength, with low muscle quantity or quality helping confirm the diagnosis. It can make everyday movement harder and affect your walking speed, balance and ability to recover if you stumble. ADT may contribute to these changes, but muscle loss alone does not necessarily establish sarcopenia.
Even if you walk normally, reduced muscle strength can make recovering from a stumble harder. If your bones are also weaker, falls may have more serious consequences. Maintaining strength helps protect your mobility and bones.
Can Fatigue Make Falls More Likely?

If you’re on hormone therapy and feeling very tired, you may find yourself moving more slowly, exercising less or paying less attention to obstacles around you. Over time, this can reduce your strength and fitness, which may make falls more likely, especially if you already have problems such as arthritis or nerve symptoms.
Fatigue does not automatically mean you’ll fall. If it affects daily activities, tell your doctor, who can check whether ADT, poor sleep, anaemia or another treatable condition contributes.
Does Hormone Therapy Affect Balance?
If you’re receiving hormone therapy, you may notice that walking or changing direction feels harder than before. ADT can reduce your muscle strength, slow your walking and increase fatigue, making it more difficult to steady yourself if you stumble. It doesn’t necessarily damage your balance system directly, but these changes can affect how safely you move.
If balance concerns you, your doctor or physiotherapist can assess how you stand, walk, turn and sit. Early assessment can help you protect mobility and reduce fall risk.
Does ADT Increase Your Fracture Risk Even If You Don’t Fall More Often?
If you’re taking ADT, falling testosterone levels can reduce your bone density and weaken your bones over time. This may increase your risk of a fracture even if you do not fall more often than before. Research has linked ADT with a higher risk of fractures, including serious fractures requiring hospital treatment.
That’s why protecting your bones matters as much as preventing falls. If you’re starting long-term hormone therapy, ask your doctor whether you need a bone-density scan and a fracture-risk assessment. Keeping your bones strong and maintaining your balance can help reduce your risk of serious injury.
Who Is Most Vulnerable to Falls and Fractures?
If you’re receiving hormone therapy, your risk of falling or breaking a bone may be higher if you’re older, have weak muscles, poor balance, nerve problems or difficulty walking. Previous fractures, arthritis, certain medicines and low body weight can also increase your risk, particularly if you’re taking newer treatments such as apalutamide.
If you’ve fallen in the past year, tell your doctor even if you weren’t injured. This can help your care team review your strength, balance and medicines and identify ways to reduce your risk of another fall or a serious fracture.
What Can Increase Fall or Fracture Risk During Hormone Therapy?
| Risk factor | Why it matters | What may help |
| Previous fall | Strong marker of future fall risk | Tell your team and ask for assessment |
| Muscle weakness | Harder to recover from a stumble | Resistance and functional exercise |
| Poor balance or gait | Increases instability | Physiotherapy assessment |
| Low bone density | Makes fractures more likely after a fall | FRAX/BMD assessment and treatment if indicated |
| Postural dizziness | Can cause instability when standing | Medicine and blood-pressure review |
| Neuropathy | Reduces sensation and foot control | Clinical assessment and mobility support |
| Vision problems | Makes hazards harder to detect | Vision review and good lighting |
Do Newer Prostate Cancer Hormone Drugs Increase Your Fall Risk Further?

If you’re taking newer prostate cancer medicines alongside hormone therapy, you may have a higher risk of falls and fractures. Research has linked drugs such as enzalutamide and apalutamide to increased risks, although the level of risk can vary depending on the treatment and your health.
This doesn’t mean you’ll definitely fall or that you should avoid treatment. If your specialist recommends one of these medicines, ask how it could affect your balance and bone health. Understanding your personal risk can help you take steps to stay safe while treating your cancer.
Research Insight
A 2020 meta-analysis by Myint and colleagues reviewed 11 randomised trials involving 11,382 men. Falls were reported in about 8% receiving androgen-receptor inhibitors versus 5% in control groups, while fractures occurred in about 4% versus 2%. These medicines were associated with higher risks of both outcomes.
A 2024 meta-analysis by Jones and colleagues also found increased fall and fracture risk when newer androgen-receptor signalling inhibitors were added to standard ADT. However, these findings reflect groups of patients and cannot predict whether you personally will fall.
Are Enzalutamide, Apalutamide and Darolutamide the Same for Fall Risk?
If you’re considering newer prostate cancer medicines, you may wonder whether some carry a higher risk of falls than others. Research suggests that the risk may vary between enzalutamide, apalutamide and darolutamide, but direct comparisons are limited.
Your specialist will consider more than fall risk when choosing treatment, including your cancer stage, other health conditions, medicines and mobility. If you’re worried about falling, discuss your concerns with your oncologist so they can help you understand the potential risks and benefits for you.
Can Blood-Pressure Medicines or Alpha-Blockers Increase Your Fall Risk?
If you’re receiving hormone therapy, medicines such as tamsulosin or certain blood-pressure treatments may cause dizziness when you stand up, particularly if your blood pressure drops. Combined with ADT-related weakness or fatigue, this can increase your risk of falling. However, not everyone taking these medicines experiences postural dizziness.
If you notice dizziness after starting a medicine or changing your dose, tell your doctor. They can review your medicines and check your blood pressure to help reduce your risk. Don’t stop prescribed medication on your own, as this could cause other problems.
Clinical Note
A fall during prostate cancer treatment should not automatically be blamed on ADT. Medication effects, low blood pressure on standing, dehydration, neuropathy, impaired vision, infection, anaemia, pain and neurological problems can all contribute.
If you report falls, near-falls or dizziness, a clinical review may include medication assessment, lying and standing blood pressure, gait and balance assessment and review of other medical causes.
Can Exercise Reduce Your Fall Risk During ADT?
If you’re taking ADT, regular exercise can help maintain your strength, balance and confidence when walking. NICE recommends offering supervised resistance and aerobic exercise at least twice weekly for 12 weeks to reduce fatigue and improve quality of life. You can also discuss suitable walking, chair stands, resistance-band exercises and balance activities with your physiotherapist.
Choose exercises that match your strength and health. If you’ve fallen before, feel unsteady or have prostate cancer that has spread to your bones, ask your doctor or physiotherapist which activities are safe for you. The aim is to protect your mobility without putting you at risk of injury.
Why Is Strength Training Particularly Important?

If you’re taking ADT, walking is helpful, but it may not be enough to maintain your muscle strength. Resistance exercises, such as standing up from a chair or using resistance bands, can help strengthen your thighs and hips, which you rely on for climbing stairs and recovering if you stumble.
You don’t need to push yourself too hard to benefit. Regular, manageable exercise can help you maintain your strength throughout treatment. If you’ve noticed muscle weakness since starting hormone therapy, ask your doctor or physiotherapist which exercises are safe and suitable for you.
Evidence Note
A 2019 meta-analysis by Chen and colleagues examined seven randomised trials. Supervised aerobic and resistance exercise improved upper- and lower-body muscle strength in men receiving ADT, but did not demonstrate a significant improvement in lean body mass.
These findings support exercise for maintaining physical function. However, stronger muscles do not guarantee that you will avoid falls, and exercise may not completely prevent ADT-related changes in muscle mass or body composition.
Should You Have a DEXA Scan Before Starting Hormone Therapy?
If you’re starting long-term hormone therapy for prostate cancer, your doctor may recommend a DEXA (also called DXA) scan to measure bone mineral density, usually at your hip and spine. This helps identify osteoporosis or low bone density. Your doctor may also use a fracture-risk tool such as FRAX, which considers clinical risk factors as well as bone density when available.
You may also need a fracture-risk assessment and regular monitoring while you’re on treatment. Ask your doctor when you should have your next bone-density scan and whether you need treatment to protect your bones. Keeping track of your bone health can help you reduce your risk of fractures as you continue treatment.
UK Guidance Note
NICE advises considering fracture-risk assessment in men receiving androgen deprivation therapy. NICE recommends bisphosphonates for men on ADT who have osteoporosis and considering denosumab when bisphosphonates are contraindicated or not tolerated.
UK expert guidance recommends using FRAX to estimate fracture risk, incorporating bone mineral density where feasible and particularly when the initial risk estimate is close to the treatment threshold. Men near but below an intervention threshold, or those moving on to additional systemic treatment, may need reassessment after around 12–18 months.
Do Calcium, Vitamin D or Bone-Protecting Medicines Help?
If you’re taking hormone therapy, getting enough calcium and vitamin D can support your bone health. Your doctor may recommend supplements if your intake or vitamin D levels are insufficient. If you have osteoporosis or a high fracture risk, bone-protecting treatment such as a bisphosphonate or denosumab may also be appropriate following an individual assessment.
These treatments can help protect your bones, but they won’t directly improve your balance or prevent every fall. Your doctor can advise which treatment is suitable for you, while regular exercise and making your home safer can help reduce your risk of falling.
What Can You Change at Home to Reduce Your Risk of Falling?
Small changes at home can reduce avoidable trip and slip hazards, particularly if treatment has affected your strength or mobility:
- Improve lighting: Keep stairs, hallways and the route to the bathroom well lit, especially at night.
- Remove trip hazards: Secure or remove loose rugs, trailing cables and clutter from walking routes.
- Use handrails: Make sure stairs have secure rails and use them when needed.
- Choose secure footwear: Shoes with a stable fit and suitable grip are safer than loose slippers.
Home changes are only one part of fall prevention. Recurrent falls, new unsteadiness or dizziness should still be medically assessed.
When Should You Ask Your Cancer Team About Fall Risk?

If you’re receiving hormone therapy, you don’t need to wait until you fall or break a bone before asking for help. Tell your cancer team if you’ve nearly fallen, feel dizzy when standing, notice weaker muscles or find walking and climbing stairs harder than before. You can also ask whether you need a bone-density scan, particularly if you’re on long-term ADT.
Your doctor may review your medicines, assess bone health, check your walking and balance, or recommend physiotherapy and suitable exercises. Tell your cancer team if your mobility changes, you lose weight unexpectedly or you start a medicine that causes dizziness. Acting early may help you remain independent and reduce preventable falls during treatment.
Myth vs Fact
| Myth | Fact |
| Everyone on ADT becomes unsteady. | Many people remain mobile; individual fall risk varies considerably. |
| ADT only affects your bones. | It can also affect muscle strength, fatigue and physical function. |
| Weaker bones make you fall. | Low bone density mainly increases the chance of fracture if a fall occurs. |
| A DEXA scan is the only way to assess fracture risk. | FRAX and clinical risk factors are also important. |
| All newer hormone drugs have the same fall risk. | Evidence suggests fall risk may differ between individual agents. |
| Calcium tablets prevent falls. | Calcium supports bone health when needed but does not directly prevent falls. |
Key Takeaways
- ADT can reduce muscle strength and bone density, but falls are usually caused by several interacting factors.
- Low bone density mainly increases the seriousness of a fall by increasing fracture risk.
- Previous falls, poor mobility, dizziness, neuropathy, frailty and certain medicines can increase risk.
- Newer androgen-receptor pathway inhibitors may increase fall and fracture risk further.
- Current evidence suggests fall risk may differ between enzalutamide, apalutamide and darolutamide, but direct comparisons are limited.
Frequently Asked Questions
1. Can hormone therapy for prostate cancer increase your risk of falls?
Yes, hormone therapy can increase your risk of falls by reducing muscle strength, increasing fatigue and affecting physical performance. Your age, mobility and other health conditions can also influence your risk.
2. Does ADT cause muscle weakness?
Yes, androgen deprivation therapy (ADT) lowers testosterone, which can gradually reduce muscle mass and strength. You may notice that climbing stairs, carrying shopping or getting up from a chair becomes more difficult.
3. Can hormone therapy weaken your bones and increase fracture risk?
Yes, ADT can reduce bone density and make your bones more vulnerable to fractures. This means a fall may cause a more serious injury, even if you do not fall more frequently.
4. Can fatigue during hormone therapy make falls more likely?
Yes, fatigue may make you less active, reduce your fitness and make everyday movements more difficult. Tell your doctor if tiredness affects your daily activities, as other treatable conditions may also contribute.
5. Do newer prostate cancer drugs increase the risk of falls?
Some newer medicines, including enzalutamide and apalutamide, have been associated with an increased risk of falls and fractures. Your specialist can explain the potential risks and benefits of your prescribed treatment.
6. Can blood-pressure medicines or tamsulosin increase fall risk during ADT?
Yes, these medicines may cause dizziness or light-headedness, particularly when you stand up. Combined with muscle weakness or fatigue, this may increase your risk of falling. Ask your doctor to review your medicines if you experience these symptoms.
7. Can exercise help prevent falls during hormone therapy?
Yes, suitable exercise can help maintain muscle strength, improve balance and support mobility. Walking, chair stands, resistance bands and appropriate balance exercises may help, but ask your doctor or physiotherapist for advice if you feel unsteady or have cancer that has spread to your bones.
8. Should you have a DEXA scan before starting hormone therapy?
Your doctor may recommend a DEXA scan to measure bone density, particularly if you are starting long-term ADT. A bone-density scan and fracture-risk assessment can help identify whether you need additional protection for your bones.
9. Can calcium, vitamin D and bone-protecting medicines reduce fracture risk?
Calcium and vitamin D support bone health, particularly if your dietary intake is insufficient. If you have osteoporosis or a high fracture risk, your doctor may recommend medicines such as bisphosphonates or denosumab.
10. When should you tell your cancer team about fall risk?
Tell your cancer team if you have fallen, nearly fallen, feel dizzy or notice worsening muscle weakness or difficulty walking. After a fall, seek emergency care if you cannot stand, have severe hip pain, develop new weakness or numbness, or have a serious head injury. You should also seek prompt assessment for suspected fractures or persistent pain, even if you can still walk.
Final Thoughts: Reducing Fall Risk During Prostate Cancer Hormone Therapy
Hormone therapy for prostate cancer can affect your muscle strength, balance, energy levels and bone health, potentially increasing your risk of falls and fractures. You can help protect yourself by staying active with suitable exercises, making your home safer and discussing bone-health checks and medication reviews with your cancer team. If you notice dizziness, muscle weakness or changes in your mobility, seek advice early so you can take steps to reduce your risk and maintain your independence.
If you’re receiving hormone therapy and are concerned about falls, muscle weakness or bone health, contact Prostate Clinic London for specialist advice about your symptoms, risk factors and available support, or to arrange a consultation tailored to your needs.
References:
- National Institute for Health and Care Excellence (2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- Jones, C. et al. (2024) ‘Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: a systematic review and meta-analysis of randomised controlled trials’, European Urology Oncology, 7(5), pp. 993–1004. Available at: https://pubmed.ncbi.nlm.nih.gov/38383277/
- Myint, Z.W. et al. (2020) ‘Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis’, JAMA Network Open, 3(11), article e2025826. Available at: https://pubmed.ncbi.nlm.nih.gov/33201234/
- Wu, F.J. et al. (2016) ‘Increased fall risk in patients receiving androgen deprivation therapy for prostate cancer’, Urology, 95, pp. 145–150. Available at: https://pubmed.ncbi.nlm.nih.gov/27318262/
- Brown, J.E. et al. (2020) ‘Guidance for the assessment and management of prostate cancer treatment-induced bone loss: a consensus position statement from an expert group’, Journal of Bone Oncology, 25, article 100311. Available at: https://pubmed.ncbi.nlm.nih.gov/32995252/
- Chen, Z. et al. (2019) ‘Supervised physical training enhances muscle strength but not muscle mass in prostate cancer patients undergoing androgen deprivation therapy: a systematic review and meta-analysis’, Frontiers in Physiology, 10, article 843. Available at: https://pubmed.ncbi.nlm.nih.gov/31333495/